AAOMS Annual Meeting

An FDA advisory committee has voted to recommend approval of a new drug for the long-term treatment of patients with hypercholesterolemia and dyslipidemia.

An FDA advisory committee has voted to recommend approval of a new drug for the long-term treatment of patients with hypercholesterolemia and dyslipidemia.

Recently, the FDA amended its breakthrough therapy designation for hepatitis C combo drug regimen, reviewed a new PCSK9 inhibitor for the treatment of high cholesterol, and approved a new treatment option...

Recently, the FDA amended its breakthrough therapy designation for hepatitis C combo drug regimen, reviewed a new PCSK9 inhibitor for the treatment of high cholesterol, and approved a new treatment option...

Recently, the FDA amended its breakthrough therapy designation for hepatitis C combo drug regimen, reviewed a new PCSK9 inhibitor for the treatment of high cholesterol, and approved a new treatment option...

A recently released statement from the FDA addresses public concerns regarding the approval of several new treatment options for chronic hepatitis C.

A recently released statement from the FDA addresses public concerns regarding the approval of several new treatment options for chronic hepatitis C.

A recently released statement from the FDA addresses public concerns regarding the approval of several new treatment options for chronic hepatitis C.

An FDA advisory committee has voted to recommend approval of a new drug for the treatment of hypoactive sexual desire disorder in premenopausal women.

The FDA has approved 2 new drugs for the treatment of irritable bowel syndrome and a new option for chronic obstructive pulmonary disease.